Evotec SE (NASDAQ: EVO) Stock Competitors & Peer Comparison
See EVO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EVO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVO | $2.02 | -4.05% | 778M | -3.09 | -$0.71 | N/A |
| TAK | $17.41 | -0.40% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.10 | +1.70% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.26 | -0.15% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.51 | -0.99% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.38 | -0.56% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.92 | +0.24% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
EVO vs TAK Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TAK trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TAK's P/E ratio is 12.52. In terms of profitability, EVO's ROE is -0.24%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EVO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EVO.Check TAK's competition here
Haleon plc (NYSE: HLN)
EVO vs HLN Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas HLN's P/E ratio is 18.28. In terms of profitability, EVO's ROE is -0.24%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EVO.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
EVO vs TEVA Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TEVA trades at $37.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TEVA's P/E ratio is 12.54. In terms of profitability, EVO's ROE is -0.24%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EVO is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
EVO vs VTRS Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while VTRS trades at $16.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas VTRS's P/E ratio is 6.39. In terms of profitability, EVO's ROE is -0.24%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EVO is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for EVO.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
EVO vs ITCI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EVO's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EVO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
EVO vs CTLT Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EVO's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EVO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EVO.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
EVO vs ELAN Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ELAN trades at $22.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ELAN's P/E ratio is 20.91. In terms of profitability, EVO's ROE is -0.24%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
EVO vs RDY Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while RDY trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas RDY's P/E ratio is 20.30. In terms of profitability, EVO's ROE is -0.24%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EVO is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for EVO.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
EVO vs LNTH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while LNTH trades at $100.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas LNTH's P/E ratio is 16.93. In terms of profitability, EVO's ROE is -0.24%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EVO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
EVO vs AMRX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AMRX's P/E ratio is 19.62. In terms of profitability, EVO's ROE is -0.24%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EVO is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
EVO vs INDV Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while INDV trades at $38.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas INDV's P/E ratio is 10.61. In terms of profitability, EVO's ROE is -0.24%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EVO is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for EVO.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
EVO vs SUPN Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SUPN trades at $47.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SUPN's P/E ratio is 15.64. In terms of profitability, EVO's ROE is -0.24%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EVO is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
EVO vs RGC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while RGC trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas RGC's P/E ratio is -356.34. In terms of profitability, EVO's ROE is -0.24%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EVO is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
EVO vs BHC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while BHC trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas BHC's P/E ratio is 1.58. In terms of profitability, EVO's ROE is -0.24%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EVO is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
EVO vs DCPH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EVO's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EVO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
EVO vs HCM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while HCM trades at $12.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas HCM's P/E ratio is 4.59. In terms of profitability, EVO's ROE is -0.24%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for EVO.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
EVO vs AVDL Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EVO's ROE is -0.24%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EVO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EVO.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
EVO vs EMBCV Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
EVO vs DVAX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EVO's ROE is -0.24%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EVO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
EVO vs PRGO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PRGO trades at $12.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PRGO's P/E ratio is 5.07. In terms of profitability, EVO's ROE is -0.24%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EVO is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
EVO vs ANIP Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ANIP trades at $74.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ANIP's P/E ratio is 9.14. In terms of profitability, EVO's ROE is -0.24%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EVO is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
EVO vs TARO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TARO's P/E ratio is 30.05. In terms of profitability, EVO's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EVO.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
EVO vs HROW Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while HROW trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas HROW's P/E ratio is 437.33. In terms of profitability, EVO's ROE is -0.24%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EVO is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for EVO.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
EVO vs PAHC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PAHC trades at $33.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PAHC's P/E ratio is 11.54. In terms of profitability, EVO's ROE is -0.24%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EVO is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
EVO vs ALVO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ALVO trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ALVO's P/E ratio is -11.79. In terms of profitability, EVO's ROE is -0.24%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EVO is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
EVO vs CRON Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CRON's P/E ratio is 30.10. In terms of profitability, EVO's ROE is -0.24%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EVO is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
EVO vs ETON Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ETON trades at $43.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ETON's P/E ratio is -594.00. In terms of profitability, EVO's ROE is -0.24%, compared to ETON's ROE of -0.06%. Regarding short-term risk, EVO is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
EVO vs PCRX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PCRX trades at $23.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PCRX's P/E ratio is 9.12. In terms of profitability, EVO's ROE is -0.24%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EVO is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
EVO vs PETQ Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EVO's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
EVO vs AMPH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AMPH trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AMPH's P/E ratio is 6.82. In terms of profitability, EVO's ROE is -0.24%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EVO is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
EVO vs COLL Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while COLL trades at $28.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas COLL's P/E ratio is 3.26. In terms of profitability, EVO's ROE is -0.24%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EVO is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for EVO.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
EVO vs IRWD Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while IRWD trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas IRWD's P/E ratio is 5.54. In terms of profitability, EVO's ROE is -0.24%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for EVO.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
EVO vs BDSI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EVO's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EVO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
EVO vs EOLS Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while EOLS trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas EOLS's P/E ratio is -25.71. In terms of profitability, EVO's ROE is -0.24%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EVO is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
EVO vs AQST Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AQST trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AQST's P/E ratio is -6.93. In terms of profitability, EVO's ROE is -0.24%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EVO is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
EVO vs TLRY Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TLRY trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TLRY's P/E ratio is -4.32. In terms of profitability, EVO's ROE is -0.24%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EVO is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
EVO vs CGC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CGC's P/E ratio is -0.62. In terms of profitability, EVO's ROE is -0.24%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EVO is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
EVO vs KMDA Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas KMDA's P/E ratio is 19.66. In terms of profitability, EVO's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EVO is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
EVO vs TKNO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TKNO trades at $7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TKNO's P/E ratio is -23.84. In terms of profitability, EVO's ROE is -0.24%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EVO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
EVO vs ALIM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EVO's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EVO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
EVO vs EMBC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while EMBC trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas EMBC's P/E ratio is 1.83. In terms of profitability, EVO's ROE is -0.24%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, EVO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
EVO vs LNDC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EVO's ROE is -0.24%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EVO is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
EVO vs ACB Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ACB trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ACB's P/E ratio is -7.80. In terms of profitability, EVO's ROE is -0.24%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EVO is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
EVO vs ORGO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ORGO trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ORGO's P/E ratio is 60.33. In terms of profitability, EVO's ROE is -0.24%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EVO is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
EVO vs TYHT Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EVO's ROE is -0.24%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
EVO vs SIGA Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SIGA trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SIGA's P/E ratio is 10.63. In terms of profitability, EVO's ROE is -0.24%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EVO is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
EVO vs OGI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while OGI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas OGI's P/E ratio is -4.96. In terms of profitability, EVO's ROE is -0.24%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EVO is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
EVO vs LFCR Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas LFCR's P/E ratio is -4.46. In terms of profitability, EVO's ROE is -0.24%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, EVO is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
EVO vs REPH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas REPH's P/E ratio is -8.04. In terms of profitability, EVO's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EVO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
EVO vs DERM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while DERM trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas DERM's P/E ratio is -17.38. In terms of profitability, EVO's ROE is -0.24%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
EVO vs CRDL Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CRDL trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CRDL's P/E ratio is -5.41. In terms of profitability, EVO's ROE is -0.24%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EVO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
EVO vs THTX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas THTX's P/E ratio is -28.83. In terms of profitability, EVO's ROE is -0.24%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
EVO vs ASRT Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EVO's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EVO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
EVO vs CPIX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CPIX trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CPIX's P/E ratio is -19.90. In terms of profitability, EVO's ROE is -0.24%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EVO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
EVO vs SCTL Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EVO's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EVO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EVO.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
EVO vs BGM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas BGM's P/E ratio is -1.01. In terms of profitability, EVO's ROE is -0.24%, compared to BGM's ROE of -0.07%. Regarding short-term risk, EVO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
EVO vs PROC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PROC's P/E ratio is 1.53. In terms of profitability, EVO's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
EVO vs OPTN Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EVO's ROE is -0.24%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EVO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EVO.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
EVO vs ZOM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EVO's ROE is -0.24%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EVO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
EVO vs GRVI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EVO's ROE is -0.24%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EVO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
EVO vs ZYBT Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, EVO's ROE is -0.24%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EVO is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
EVO vs TLPH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TLPH's P/E ratio is -4.52. In terms of profitability, EVO's ROE is -0.24%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
EVO vs ZYNE Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EVO's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EVO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
EVO vs SSIC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EVO's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EVO is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
EVO vs VLNS Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EVO's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, EVO is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
EVO vs DRRX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EVO's ROE is -0.24%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EVO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
EVO vs INCR Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while INCR trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas INCR's P/E ratio is -2.23. In terms of profitability, EVO's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EVO is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for EVO.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
EVO vs JUPW Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EVO's ROE is -0.24%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EVO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EVO.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
EVO vs CPHI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CPHI trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CPHI's P/E ratio is -1.72. In terms of profitability, EVO's ROE is -0.24%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
EVO vs QLI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas QLI's P/E ratio is -4.92. In terms of profitability, EVO's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EVO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
EVO vs HEXO Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EVO's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EVO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
EVO vs RMTI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while RMTI trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas RMTI's P/E ratio is -7.42. In terms of profitability, EVO's ROE is -0.24%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EVO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
EVO vs AYTU Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AYTU trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AYTU's P/E ratio is -1.23. In terms of profitability, EVO's ROE is -0.24%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EVO is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for EVO.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
EVO vs TXMD Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas TXMD's P/E ratio is 105.96. In terms of profitability, EVO's ROE is -0.24%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EVO is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for EVO.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
EVO vs CYTH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EVO's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EVO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
EVO vs EVOK Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EVO's ROE is -0.24%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, EVO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EVO.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
EVO vs OPTH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while OPTH trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas OPTH's P/E ratio is -17.38. In terms of profitability, EVO's ROE is -0.24%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, EVO is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
EVO vs ACRX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EVO's ROE is -0.24%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
EVO vs BFRIW Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.24%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, EVO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for EVO.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
EVO vs COSM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas COSM's P/E ratio is -0.29. In terms of profitability, EVO's ROE is -0.24%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EVO is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
EVO vs AGRX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EVO's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EVO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
EVO vs NLTX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EVO's ROE is -0.24%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EVO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
EVO vs LCI Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas LCI's P/E ratio is -0.04. In terms of profitability, EVO's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EVO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
EVO vs ADMP Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EVO's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EVO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
EVO vs YCBD Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while YCBD trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas YCBD's P/E ratio is -1.49. In terms of profitability, EVO's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for EVO.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
EVO vs GELS Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while GELS trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas GELS's P/E ratio is -1.14. In terms of profitability, EVO's ROE is -0.24%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EVO is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
EVO vs MNK Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas MNK's P/E ratio is -0.44. In terms of profitability, EVO's ROE is -0.24%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EVO.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
EVO vs FLGC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.24%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EVO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
EVO vs UPC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while UPC trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas UPC's P/E ratio is -0.75. In terms of profitability, EVO's ROE is -0.24%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
EVO vs SBFM Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SBFM trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SBFM's P/E ratio is -0.20. In terms of profitability, EVO's ROE is -0.24%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, EVO is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
EVO vs PLXP Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EVO's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EVO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
EVO vs SHPH Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SHPH trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SHPH's P/E ratio is -0.20. In terms of profitability, EVO's ROE is -0.24%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, EVO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
EVO vs ATNX Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EVO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
EVO vs SNOA Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SNOA trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SNOA's P/E ratio is -1.16. In terms of profitability, EVO's ROE is -0.24%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EVO is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
EVO vs PROCW Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas PROCW's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
EVO vs RDHL Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while RDHL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas RDHL's P/E ratio is 0.12. In terms of profitability, EVO's ROE is -0.24%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, EVO is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
EVO vs SXTC Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while SXTC trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas SXTC's P/E ratio is 1.18. In terms of profitability, EVO's ROE is -0.24%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, EVO is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
EVO vs YCBD-PA Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, EVO's ROE is -0.24%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
EVO vs CYTHW Comparison August 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 778M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, EVO is priced at $2.02 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.09, whereas CYTHW's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, EVO is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for EVO.Check CYTHW's competition here